A biopsy is the only way to determine if this is a primary cutaneous neoplasm or a cutaneous metastasis from a visceral carcinoma.

A 63-year-old man presented for medical attention for a slowly growing, 8-cm skin lesion on the back. The oozing mass was slightly tender and often bled spontaneously.
Key point: This appears to be a tumor. The size and history of bleeding suggest a malignancy. There is no way to know if this is a primary cutaneous neoplasm (basal cell or squamous cell carcinoma, soft tissue sarcoma, malignant melanoma) or a cutaneous metastasis from visceral carcinoma without performing a biopsy. Aside from routine histology, tumor markers and gene mutations may be important in determining optimal therapy. A biopsy disclosed malignant melanoma. A systemic workup revealed widespread, multi-organ metastatic disease.
Treatment: The primary cutaneous lesion was excised. Because of the presence of the V600E B-raf mutation, vemurafenib chemotherapy was started, and the patient responded well.
Note: New, targeted therapies offer hope of prolonged progression-free survival-and even cure-in situations in which the prognosis was previously quite grim.
Atopic Dermatitis: The Pipeline and Clinical Approaches That Could Transform the Standard of Care
September 24th 2025Patient Care tapped the rich trove of research and expert perspectives from the Revolutionizing Atopic Dermatitis 2025 conference to create a snapshot of the AD care of the future.